Standard BioTools Inc.
NASDAQTotal Valuation
Standard BioTools Inc. carries a market capitalization of 301.35M, placing it among publicly traded companies globally. Its enterprise value stands at -126.03M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 301.35M |
| Enterprise Value | -126.03M |
Share Statistics
Standard BioTools Inc. currently has 392.12M shares outstanding.
| Shares Outstanding | 392.12M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Standard BioTools Inc. trades at a trailing price-to-earnings ratio of 3.75. The price-to-sales ratio is 3.76, and the price-to-book ratio stands at 0.60.
| PE Ratio | 3.75 |
| PS Ratio | 3.76 |
| PB Ratio | 0.60 |
| P/TBV Ratio | 0.60 |
| P/FCF Ratio | -4.08 |
| P/OCF Ratio | -3.96 |
Enterprise Valuation
| EV / Sales | 7.02 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Standard BioTools Inc. maintains a current ratio of 9.10, meaning it holds 9.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 5.20, indicating elevated leverage, while an interest coverage ratio of -3,809.53 demonstrates limited ability to service its debt obligations.
| Current Ratio | 9.10 |
| Quick Ratio | 8.67 |
| Debt / Equity | 5.20 |
| Debt / EBITDA | -0.49 |
| Interest Coverage | -3,809.53 |
Financial Efficiency
| Return on Equity (ROE) | 17.61 |
| Return on Assets (ROA) | 14.34 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 2.03 |
Taxes
| Income Tax | -37.05M |
| Effective Tax Rate | N/A |
Stock Price Statistics
Standard BioTools Inc.'s stock has declined approximately -45.01429% over the past 52 weeks. The 50-day moving average sits at 0.76, while the 200-day moving average is 1.03.
| Beta (5Y) | N/A |
| 52-Week Price Change | -45.01429% |
| 50-Day Moving Average | 0.76 |
| 200-Day Moving Average | 1.03 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Standard BioTools Inc. generated 84.60M in revenue and converted that into 84.91M in net income, yielding earnings per share of -0.14. EBITDA reached -57.14M, while operating income came in at -62.64M.
| Revenue | 84.60M |
| Gross Profit | 42.71M |
| Operating Income | -62.64M |
| Pretax Income | -90.98M |
| Net Income | 84.91M |
| EBITDA | -57.14M |
| EBIT | -62.64M |
| Earnings Per Share (EPS) | -0.14 |
Balance Sheet
Standard BioTools Inc. holds 476.72M in cash and equivalents against 28.09M in total debt, resulting in a net debt position of -269.73M. Total book value stands at 539.97M, with working capital of 460.07M providing operational flexibility.
| Cash & Cash Equivalents | 476.72M |
| Total Debt | 28.09M |
| Net Debt | -269.73M |
| Equity (Book Value) | 539.97M |
| Book Value Per Share | 1.38 |
| Working Capital | 460.07M |
Cash Flow
Standard BioTools Inc. produced -80.30M in operating cash flow over the past twelve months. After subtracting -2.28M in capital expenditures, free cash flow totaled -82.58M - equivalent to -0.21 per share.
| Operating Cash Flow | -80.30M |
| Capital Expenditures | -2.28M |
| Free Cash Flow | -82.58M |
| FCF Per Share | -0.21 |
Margins
Standard BioTools Inc. operates with a gross margin of 50.49, reflecting its pricing power and cost economics. The operating margin of -74.04 and net profit margin of 100.37 provide insight into operational efficiency.
| Gross Margin | 50.49 |
| Operating Margin | -74.04 |
| Pretax Margin | -107.55 |
| Profit Margin | 100.37 |
| EBITDA Margin | -67.55 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -0.10 |
| FCF Yield | -24.53 |
Scores
Standard BioTools Inc. posts an Altman Z-Score of 0.31, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 0.31 |